Biogen Inc (BIIB) - Total Liabilities
Based on the latest financial reports, Biogen Inc (BIIB) has total liabilities worth $11.18 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biogen Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Biogen Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Biogen Inc to evaluate short-term liquidity relative to the company's equity base.
Biogen Inc Competitors by Total Liabilities
The table below lists competitors of Biogen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SEVEN+I HLDGS UNSP.ADR1/2
F:S6MA
|
Germany | €7.63 Trillion |
|
RYANAIR HLDGS ADR NEW/5
F:RY4D
|
Germany | €7.26 Billion |
|
GE HealthCare Technologies Inc.
NASDAQ:GEHC
|
USA | $26.23 Billion |
|
SHINHAN FINL ADR/1 SW5000
F:KSF1
|
Germany | €725.64 Trillion |
|
Muyuan Foodstuff Co Ltd
SHE:002714
|
China | CN¥89.89 Billion |
|
Arch Capital Group Ltd
F:RSK
|
Germany | €57.26 Billion |
|
CenterPoint Energy Inc
NYSE:CNP
|
USA | $36.39 Billion |
|
Hanwha Ocean Co., Ltd
KO:042660
|
Korea | ₩13.06 Trillion |
Liability Composition Analysis (1985–2025)
This chart breaks down Biogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIIB stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biogen Inc (1985–2025)
The table below shows the annual total liabilities of Biogen Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $11.18 Billion | -1.33% |
| 2024-12-31 | $11.33 Billion | -5.91% |
| 2023-12-31 | $12.05 Billion | +7.88% |
| 2022-12-31 | $11.17 Billion | -13.56% |
| 2021-12-31 | $12.92 Billion | -7.29% |
| 2020-12-31 | $13.93 Billion | +0.27% |
| 2019-12-31 | $13.90 Billion | +13.36% |
| 2018-12-31 | $12.26 Billion | +10.88% |
| 2017-12-31 | $11.05 Billion | +2.85% |
| 2016-12-31 | $10.75 Billion | +6.10% |
| 2015-12-31 | $10.13 Billion | +189.22% |
| 2014-12-31 | $3.50 Billion | +8.02% |
| 2013-12-31 | $3.24 Billion | +2.41% |
| 2012-12-31 | $3.17 Billion | +20.73% |
| 2011-12-31 | $2.62 Billion | -0.77% |
| 2010-12-31 | $2.64 Billion | +15.42% |
| 2009-12-31 | $2.29 Billion | -14.33% |
| 2008-12-31 | $2.67 Billion | -13.62% |
| 2007-12-31 | $3.09 Billion | +120.56% |
| 2006-12-31 | $1.40 Billion | -3.97% |
| 2005-12-31 | $1.46 Billion | -37.54% |
| 2004-12-31 | $2.34 Billion | -4.54% |
| 2003-12-31 | $2.45 Billion | +495.44% |
| 2002-12-31 | $411.57 Million | +10.57% |
| 2001-12-31 | $372.21 Million | +14.37% |
| 2000-12-31 | $325.45 Million | +9.05% |
| 1999-12-31 | $298.44 Million | +44.80% |
| 1998-12-31 | $206.10 Million | -25.74% |
| 1997-12-31 | $277.53 Million | +84.77% |
| 1996-12-31 | $150.20 Million | +74.21% |
| 1995-12-31 | $86.22 Million | +79.90% |
| 1994-12-31 | $47.93 Million | +50.72% |
| 1993-12-31 | $31.80 Million | +21.37% |
| 1992-12-31 | $26.20 Million | +85.82% |
| 1991-12-31 | $14.10 Million | +10.16% |
| 1990-12-31 | $12.80 Million | +113.33% |
| 1989-12-31 | $6.00 Million | -53.49% |
| 1988-12-31 | $12.90 Million | +0.78% |
| 1987-12-31 | $12.80 Million | +10.34% |
| 1986-12-31 | $11.60 Million | +6.42% |
| 1985-12-31 | $10.90 Million | -- |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more